Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation (PARABLE)
A Randomised, Controlled, Double-blind, Double-dummy, Clinical Trial Comparing Sacubitril-Valsartan Versus Valsartan in Asymptomatic, Stage A/B HFpEF Patients With Elevated Natriuretic Peptide and Abnormal LAVI. (Previously NCT02682719)
Sponsor: Mark Ledwidge
A PHASE2 clinical study on Atrial Arrhythmia and Atrial Remodeling, this trial is ongoing. The trial is conducted by Mark Ledwidge and has accumulated 6 data snapshots since 2015. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jun 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2021 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 1 earlier version
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mark Ledwidge
- The Heartbeat Trust
For direct contact, visit the study record on ClinicalTrials.gov .